First Line Therapy for High Risk Acute GVHD

NCT04061876 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

198

Enrollment

OTHER

Sponsor class

Conditions

aGVHD
Stem Cell Transplant Complications

Interventions

DRUG: Ruxolitinib
DRUG: Corticosteroid

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]